Immunotherapy has been a remarkable clinical advancement in the treatment of cancer. T
cells are pivotal to the efficacy of current cancer immunotherapies, including immune …

Hepatocellular carcinoma (HCC) is one of the most common solid malignancies worldwide.
A large proportion of patients with HCC are diagnosed at advanced stages and are only …

The transformative success of antibodies targeting the PD-1 (programmed death 1)/B7-H1
(B7 homolog 1) pathway (anti-PD therapy) has revolutionized cancer treatment. However …

Recent advances in cancer immunotherapy—ranging from immune-checkpoint blockade
therapy to adoptive cellular therapy and vaccines—have revolutionized cancer treatment …

Anti-PD-1 treatment has shown unprecedented clinical success in the treatment of non-small-
cell lung cancer (NSCLC), but the underlying mechanisms remain incompletely understood …

Combination therapy with PD-1 blockade and IL-2 is highly effective during chronic
lymphocytic choriomeningitis virus infection. Here we examine the underlying basis for this …

Immune checkpoint blockade has revolutionized the field of oncology, inducing durable anti-
tumour immunity in solid tumours. In patients with advanced prostate cancer …

T cell exhaustion limits antitumor immunity, but the molecular determinants of this process
remain poorly understood. Using a chronic stimulation assay, we performed genome-wide …

Within the past decade, the field of immunotherapy has revolutionized the treatment of many
cancers with the development and regulatory approval of various immune-checkpoint …

Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable success in
hematological malignancies but remains ineffective in solid tumors, due in part to CAR T cell …